Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | ADG126 |
| Trade Name | |
| Synonyms | ADG-126|ADG 126 |
| Drug Descriptions |
ADG126 is a monoclonal antibody that binds to and inhibits CTLA-4 expressed on T lymphocytes, potentially leading to enhanced antitumor immune response (J Clin Oncol 40, no. 16_suppl (June 01, 2022) e17601-e17601). |
| DrugClasses | CTLA4 Antibody 33 Immune Checkpoint Inhibitor 150 |
| CAS Registry Number | NA |
| NCIT ID | C179276 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| ADG106 + ADG126 | ADG106 ADG126 | 0 | 1 |
| ADG126 | ADG126 | 0 | 2 |
| ADG126 + Bevacizumab + Pembrolizumab + Trifluridine-tipiracil hydrochloride | ADG126 Bevacizumab Pembrolizumab Trifluridine-tipiracil hydrochloride | 0 | 1 |
| ADG126 + Fruquintinib + Pembrolizumab | ADG126 Fruquintinib Pembrolizumab | 0 | 1 |
| ADG126 + Pembrolizumab | ADG126 Pembrolizumab | 0 | 1 |
| ADG126 + SAR445877 | ADG126 SAR445877 | 0 | 1 |
| ADG126 + unspecified PD-1 antibody | ADG126 unspecified PD-1 antibody | 0 | 1 |